1. Generics Bulletin
  2. >>Products

Krka Introduces Cardiovascular Range To New Eastern European Markets

 
• By Akriti Seth

Reporting double-digit growth in the first half of 2019, Krka says it has mined marketing opportunities in new eastern European markets by introducing its established treatments for cardiovascular diseases

Opportunities
Krka is rolling out a range of combination cardiovascular drugs in Eastern Europe and the Commonwealth of Independent States • Source: Shutterstock

[Krka] says it is expanding its marketing opportunities in new eastern European markets like Kazakhstan, Kyrgyzstan, Azerbaijan, Georgia, Ukraine and Uzbekistan, by introducing its established treatments of cardiovascular diseases.

Among the combination drugs launched were Niperten Combi (amlodipine/bisoprolol) tablets in Kazakhstan, Valodip (valsartan/amlodipine) in Kyrgyzstan and Roxera Combi (rosuvastatin/amlodipine) film-coated tablets in Azerbaijan, as well as Co-Vamloset (valsartan/amlodipine/hydrochlorothiazide) in Georgia and Teldipin (telmisartan/amlodipine) in Ukraine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

More from Generics Bulletin